Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I agree with you Ruck on Vulpes they probably thought whats wrong with doing another fund raise when we have some excellent data, with the share price at 60p and still a few million of the 25 million not spent just a thought maybe they did have our best interest at heart and less dilution.
Its more than likely that the small trades are brokers selling shares to cover their fees when you have not enough money in your account to cover them to settle up. It happened to me once they didnt charge a fee though. Most brokers have the right to sell some of your holding in their terms and conditions to settle any fees.
The only clear signal i take from this is positive loan notes are repaid before shareholders if a company goes bust, so it would make sense for anyone holding them to keep hold for as long as possible. So why convert now? can only be for voting reasons i still think there is the smell of a takeover coming i said a week or so ago they may have had an informal approach.
The takeover maybe from within redmile have recent history interesting to see what pans out but this guy wont be selling early this time just my opinion as always.
RNS out
It could be anybody behind this investment even if we get the name of the holder could be Elon himself via a 3rd party Lol that would be a strategic move new kid on the block gets in by the back door.
Isb true but thats usually the case when the money invested in a start up company not one with so many irons in the fire which any one could catapult us too a.........strategic inflection point.
Ok if thats the case when the name comes out who invested 15 million into See they are idiots are they... think about it.
Seen so many posts on see 4th in leader board wow, slightly bemused by it all but hey circa 15 million investment not to be refused if for the right strategic move.
r
Only if if it was a formal offer how many times do you read in the press through speculation when a share goes up then company will come out and say yeah we had some interest but we are not interested. They have to make it a formal offer.
Morning all, I will stick my neck out with the following assumption.
The Americans got wind of us back in June when we were featured in a peer reviewed American journal.
They will have scientists helping them with their decisions to invest, so they make an investment because they like what they see not just a one trick pony.
Now what i am intrigued with suddenly we need more money when the ink has not dried on their other investment, the sudden bit in my opinion has come about through the conclusion of the mab deal not in a deal for the mab but a cheeky low ball offer for the whole company which resulted in the more than doubling of the share price. just doesnt add up to invest so much money when they havn't spent the previous amount.
Just my take on it best regards to all.
I think this RNS from the 12th 0f June may have set the ball rolling with our American investors.
Peer reviewed publication highlights potential of AvidiMab™ to enhance the potency of any therapeutic antibody
Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to note the publication of its manuscript in Cancer Research, a journal of the American Association of Cancer Research (AACR), entitled: "Engineering the human Fc-region enables direct cell killing by cancer glycan-targeting antibodies without the need for immune effector cells or complement".1
The paper describes how Scancell's AvidiMab™ modifications to the constant region (Fc) of any antibody can improve avidity, or strength of interaction, between the antibody and its target antigen, thereby improving the antibody's potential therapeutic properties. This same modification also has demonstrated that Scancell's own tumour-associated glycan (TaG) antibodies can directly kill tumour cells.
In recent years, antibodies have become the best-selling drugs in the pharmaceutical market and have been approved for treating various human diseases, including many cancers, autoimmune, metabolic and infectious diseases. The global therapeutic monoclonal antibody market is estimated to be US$150 billion in 2019 and predicted to grow to US$300 billion by 2025.2
The ability to increase the potential therapeutic properties of any antibody would therefore be seen as highly advantageous. Scancell has used its AvidiMab™ technology to increase the avidity of its TaG antibodies, and these are currently being evaluated for the treatment of cancer. They are also being developed as antibody-drug conjugates (ADC).3
Professor Lindy Durrant, Chief Scientific Officer of Scancell and Corresponding Author, commented:
"We are pleased to have our work published in the prestigious, peer reviewed journal, Cancer Research. Our AvidiMab™
Who knows they may have got wind of some more American interest and have upped the stakes with a larger investment .
You are spot on with your thoughts Chester.
Douve/WTP if you check out Redx from December last year the Redmile involvement all too familiar to me only difference Scancell had more money Redx needed it urgently. But they are still listed (ouch sorry this hurts) they only achieved little over 50% acceptances and i think they where caught out by the imminent deal coming through to make it conditional quick enough.
Douve if they try to take out too low dont accept the offer, Redx still listed 70p (ouch) after offering 15p for them
Exactly WTP wouldnt play poker against these guys but a little wiser now they offerd 15p for Redx which i accepted (idiot).
But on the good side they can see a great investment so happy to go along with them now i know a little bit about them.
I was in Redx too very similar pattern they come in with an offer to buy the company just before a major deal with Astra Zeneca I sold out cheap with them but not this time. Though have taken 10% out this morning to fund open offer and think may weaken from here a little GLA
Still think it could be job working for Cobra too take Scancell product(s) to production because we may have more than one in the near future yes, i hope so.
Also from job advert
As a Group Leader in Medicinal Chemistry, you’ll lead and grow a team of experienced Synthetic & Medicinal Chemists, with an excellent reputation in the industry, to ensure world-class delivery for drug discovery projects of all types, and act as a key point of contact for customers across the world.
Ivy CRO - cancer research organization ?
Also this job in Nottingham.
https://jobs.newscientist.com/en-gb/job/1401718509/group-leader-medicinal-chemistry-nottingham-c-45k/?LinkSource=SimilarJobPlatform
Could this be job interface working for Cobra but developing product with Scancell bit coincidental.
Well i dont think a fundraise is needed unless to fund something mega along with a NASDAQ listing which would get America onboard.......
This rns will generate interest with green funds too when word gets round plenty to like about this.